Although poorly differentiated endometrial endometrioid carcinoma, similarly to USC, may often be resistant/refractory to standard treatment modalities, these tumors are molecularly different from USC (6) and, accordingly, warrant separate analysis for TROP2 expression. Here, TACSTD2 is linked to endometrial endometrioid carcinoma.